Taming Bacterial Toxins into an Anticancer Platform.

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Background:

• Uncontrolled cancer cell growth leads to hypoxia, increasing Sialyl Lewis X (SLeX) expression.
• SLeX expression correlates with poor prognosis and low survival rates across various cancers.
• Targeting SLeX shows promise in inhibiting cancer cell migration and inducing cell death.

Purpose of the Study:

• To construct and evaluate the anticancer efficacy of a novel fusion protein, SSL11-PE24^M10.
• To assess the therapeutic potential of SSL11-PE24^M10 against SLeX-expressing cancers.

Main Methods:

• Construction and purification of the SSL11-PE24^M10 fusion protein.
• In vitro testing of anticancer activities in human cancer cell lines.
• Evaluation of toxicity in normal human lung epithelial cells and immunogenicity in mice.

Main Results:

• SSL11-PE24^M10 effectively entered cancer cells, induced dose-dependent cell death, and inhibited cell migration.
• The fusion protein demonstrated lower toxicity in normal cells compared to the PE24^M10 component alone.
• SSL11-PE24^M10 elicited low immunogenicity in murine models.

Conclusions:

• SSL11-PE24^M10 is a promising therapeutic candidate for SLeX-overexpressing cancers, particularly those prone to metastasis.
• The fusion protein offers a targeted approach with reduced toxicity and immunogenicity.
• This study provides a novel strategy for cancer therapy development.